You are here

Child Pneumococcal Serotype Epidemiology In Greece

Last updated on May 9, 2018

FOR MORE INFORMATION
Study Location
Agia Sophia Children's Hospital
Athens, Attiki, 115 27 Greece
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0-14
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Children aged 14 years old or less.

- Hospitalized in a participating healthcare facility with an IPD.

- IPD will be confirmed by isolation of S. pneumoniae from a sterile body site.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Children > 14 years of age

- Unconfirmed IPD

NCT01111214
Pfizer
Completed
Child Pneumococcal Serotype Epidemiology In Greece

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Pneumococcal Infections
NCT03512288
All Genders
0+
Years
Multiple Sites
Pneumococcal Infections, Pneumococcal Conjugate Vaccine
NCT03574389
All Genders
0+
Years
Huaian, Jiangsu
Child Pneumococcal Serotype Epidemiology In Greece
Incidence And Serotypes Of Invasive Pneumococcal Disease, After The Introduction Of The Heptavalent Conjugated Vaccine In Greece

Streptococcus pneumoniae is a major cause of pneumonia, sepsis, bacteremia, and pneumococcal meningitis among infants and children worldwide. The 7-valent conjugate pneumococcal vaccine (Prevenar) has been introduced in the Greek Market in 2004. Additionally, as of 2006 Prevenar has been included in the Greek National Immunization Program.

The effect of the mass vaccination on the incidence of pneumococcal serotypes involved in the occurring invasive pneumococcal disease, is an important factor to consider for the introduction of the 13-valent pneumococcal conjugate vaccine.

open label, one group Purposive sampling of hospitalized children ?14 years of age with confirmed IPD
Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
Hospitalized children in participating centers
Pneumococcal Disease
Other: no intervention
There is no intervention. This is a non interventional study.
group 1
Hospitalized children ?14 years of age with invasive pneumococcal disease
Intervention: Other: no intervention
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
457
November 2012
November 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Children aged 14 years old or less.
  • Hospitalized in a participating healthcare facility with an IPD.
  • IPD will be confirmed by isolation of S. pneumoniae from a sterile body site.

Exclusion Criteria:

  • Children > 14 years of age
  • Unconfirmed IPD
Sexes Eligible for Study: All
up to 14 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Greece
 
 
NCT01111214
0887X1-4434
B1841010
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
January 2013

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now